Pancreatic Tumor – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pancreatic Tumor – Drugs In Development, 2024 report and make more profitable business decisions.
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells. Small changes in the cellular DNA result in uncontrolled multiplication and accumulation of cells into a tumor. Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine, and loss of appetite. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis.
The Pancreatic Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Pancreatic Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Tumor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pancreatic Tumor | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pancreatic Tumor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pancreatic Tumor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pancreatic Tumor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AB Pharma LtdAmgen Inc
AVEO Pharmaceuticals Inc
Changchun GeneScience Pharmaceutical Co Ltd
DevaCell Inc
F. Hoffmann-La Roche Ltd
Medicenna Therapeutics Corp
Merck & Co Inc
Molecular Templates Inc
OncoSec Medical Inc
Rin Institute Inc
Seagen Inc
Taiho Oncology Inc
The University of British Columbia
Vanquish Oncology Inc
Xuzhou Medical University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pancreatic Tumor reports